Expression and Regulation of Endothelial Nitric Oxide Synthase by Vascular Endothelial Growth Factor in ECV 304 Cells

Nitric oxide (NO) seems to play a pivotal role in the vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation. This study was designed to investigate the role and intracellular signal pathway of endothelial nitric oxide synthase (eNOS) activation induced by VEGF. ECV 304 cells were treated with VEGF165 and then cell proliferation, eNOS protein and mRNA expression levels were analyzed to elucidate the functional role of eNOS in cell proliferation induced by VEGF. After exposure of cells to VEGF165, eNOS activity and cell growth were increased by approximately two-fold in the VEGF165-treated cells compared to the untreated cells. In addition, VEGF stimulated eNOS expression at both the mRNA and protein levels in a dose-dependent manner. Phosphatidylinositol-3 kinase (PI-3K) inhibitors were used to assess PI-3K involvement in eNOS regulation. LY294002 was found to attenuate VEGF-stimulated eNOS expression. Wortmannin was not as effective as LY294002, but the reduction effect was detectable. Cells activated by VEGF showed increased ERK1/2 levels. Moreover, the VEGF-induced eNOS expression was reduced by the PD98059, MAPK pathway inhibitor. This suggests that eNOS expression might be regulated by PI-3K and the ERK1/2 signaling pathway. In conclusion, VEGF165 induces ECV 304 cell proliferation via the NO produced by eNOS. In addition, eNOS may be regulated by the PI-3K or mitogen-activated protein kinase pathway.

Key Words: Angiogenesis; Nitric-Oxide Synthase

INTRODUCTION

The vascular endothelial growth factor (VEGF) is known to be a vascular permeability factor and an endothelial cell growth factor secreted by both the smooth muscle and endothelial cells. VEGF is a secreted endothelial cell mitogen and play a major role in hypoxia-stimulated angiogenesis (1). Vascular endothelial cells have binding sites with a high affinity for VEGF and VEGF itself is thought to play a major role both in preserving vascular endothelial cells and vascular endothelial cell recovery (2). VEGF is regulated by the Flt-1 and Flk-1/KDR receptors, which are part of the tyrosine kinase family (3, 4). Flt-1, which has a higher affinity for VEGF than Flk-1/KDR, is thought to mainly regulate the formation of cellular architecture, while Flk-1/KDR is involved in cell proliferation (5-8).

However, the subsequent mechanism of signal transduction following the VEGF receptor in vascular cells is uncertain. The effects of VEGF in permeability and vascular tension are associated with nitric oxide (NO) formation (9, 10), and numerous studies have reported a correlation between the endothelial proliferating effect of VEGF with NO (11-13). Angiogenesis associated with NO was investigated in mouse arteries in vitro or in vivo vascular injury experiments. In experiments using arteries or arterioles, VEGF protein expression is increased while the NO metabolite concentration initially decreases and then increases thereafter. However, in arteries injured with balloons, addition of VEGF protein or naked VEGF cDNA re-stimulates endothelial proliferation, and recovers the endothelial cell-dependent vascular response (14, 15). Such effects correlate VEGF with endothelial cell growth, and this new vascular formation is thought to be due to the continuous maintenance of NO formation. Also, the addition of NO synthase (NOS) inhibitors in endothelial cell cultures inhibited VEGF-induced cell growth in addition to the reticular formation of newly synthesized vascular tissues (12).

However, the exact mechanism of action of VEGF in NO formation is still unclear. Recently, several reports have demonstrated that VEGF-stimulated NO production requires activation of the phosphatidylinositol 3-kinase (PI-3K) and mitogen-activated protein kinase (MAPK) signal transduction pathways (16, 17).

This study was designed to elucidate whether the changes
in eNOS activity by VEGF are simply due to variations in the eNOS activation rate, or due to the changes in the eNOS protein and mRNA levels. In addition, whether or not PI-3K, a known crucial factor in cell growth, and extracellular regulated kinase 1/2 (ERK1/2), a MAPK family, are associated with the eNOS protein expression by VEGF was examined.

MATERIALS AND METHODS

Materials

The recombinant VEGF protein, [3H] citrulline, ([γ-32P]dCTP, ([γ-32P]ATP, and enhanced chemiluminescence (ECL) reagents were purchased from Amersham (Buckinghamshire, U.K.). M199 and the phosphate-buffered saline were obtained from Gibco BRL (Grand Island, NY, U.S.A.). The fetal calf serum was purchased from Hyclone (Logan, UT, U.S.A.). The rabbit polyclonal eNOS antibodies, and the anti-rabbit IgG peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). The phospho-ERK antibodies and phospho-p38 antibodies were purchased from New England BioLab (Beverly, MA, U.S.A.). The LY294002, wortmannin, and PD98059 were purchased from Sigma (St. Louis, MO, U.S.A.). The phospho-ERK antibodies and phospho-p38 antibodies were purchased from New England BioLab (Beverly, MA, U.S.A.). The LY294002, wortmannin, and PD98059 were purchased from Sigma (St. Louis, MO, U.S.A.).

Cell Culture

ECV 304 was obtained from the American Type Culture Collection. The cells were cultured in M199 supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% fetal calf serum. The cells were grown at 37°C, 5% CO2 in fully humidified air and subcultured twice weekly. The cells were seeded on 12-well plates at 1×105 cells/well or 6-well plates at 5×106 cells/well. The cells were stimulated for set times ranging from 1 hr to 24 hr in the presence of VEGF with or without the inhibitors. The viability of the ECV 304 cells in the presence of the VEGF was assessed after different days of incubation by the Trypan Blue exclusion method.

Quantitation of Intracellular NO generation

The eNOS enzyme activity was quantified by L-[3H] citrulline formation from L-[3H] arginine. Briefly, the cells in a given well of the 6-well plate were incubated in 800 μL of a buffer containing 25 mM HEPES, pH 7.3, 109 mM NaCl, 5.4 mM KCl, 0.9 mM CaCl2, 1 mM MgSO4, and 25 mM glucose at 37°C for 1 hr. The eNOS activity was assayed by adding a mixture of unlabeled 10 μM L-arginine, 10 μCi/mL L-[3H] arginine, and VEGF or the vehicle to the culture. Following incubation at 37°C for 10 min, the cells were washed with ice-cold phosphate-buffered saline (PBS), scraped into 2 mL of a solution containing 20 mM sodium acetate, 1 mM L-citrulline, 2 mM EDTA, and 2 mM EGTA, pH 5.5, followed by sonication. An aliquot was withdrawn to determine the total protein concentration and the total amount of cellular H2 incorporation. The remaining sample was applied to the Dowex 50W-X8 400 column to separate L-[3H] citrulline. The flow-through fraction was analyzed by liquid scintillation counting.

Western blotting and MAPK activation

The ECV 304 cells were plated in a 6-well plate and treated with VEGF with various inhibitors. They were then washed with cold-PBS, scraped off, pelleted at 700×g and at 4°C. The cell pellet was resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, and protease inhibitor cocktail). The preparation was then cleared by centrifugation and the supernatant saved as a whole-cell lysate. The proteins (50 μg) were separated by 8% reducing SDS-PAGE and electroblotted in 20% methanol, 25 mM Tris, and 192 mM glycine onto a nitrocellulose membrane. The membrane was then blocked with 5% non-fat dry milk in TTBS (25 mM Tris-HCl, 150 mM NaCl, and 0.2% Tween-20) and subsequently incubated with the eNOS antibody for 4 hr. Subsequently, the membrane was washed and incubated for 1 hr with secondary antibodies conjugated to HRP. Finally, the membrane was washed and developed using an enhanced ECL system. The activation of ERK and p38 was determined by Western blotting using antibodies specific for phosphorylated, active forms of the corresponding MAPKs. As loading controls, Western blots were also performed using antibody against total ERK in a 1:1,000 dilution.

RT-PCR

The ECV 304 cells (2×106 cells) were cultured and harvested. The cells were then washed three times with PBS containing 2% bovine serum albumin (BSA), and the RNA was isolated using a Trizol Reagent kit (Molecular Research Center, Cincinnati, OH, U.S.A.). A modified reverse transcriptase-polymerase chain reaction (RT-PCR) technique was used to analyze eNOS at the mRNA level. Briefly, the total RNA was reverse transcribed into cDNA using the RT-PCR kit. Oligonucleotide primers for the PCR were designed according to the published sequence for human eNOS (sense primer: ATT ATC CAG AGC GAG AGC CT; antisense primer: TCT TGC CAC CAC TGT GTT GT). The PCR conditions for eNOS production was 24 cycles of denaturation (95°C/1 min), annealing (60°C/1 min), and extension (72°C/1 min) in the
presence of 2.5 mg MgCl₂, followed by a final extension at 72°C for 20 min. Oligonucleotide primers for β-actin were used as internal control for RT-PCR. The PCR products were separated by electrophoresis using a 2% agarose gel in TBE buffer containing 50 ng/mL of ethidium bromide.

**Statistical analysis**

Statistical analysis was performed using SPSS 10.0 for Windows. Data were given as mean ± standard deviation and comparison of the two groups was made by unpaired Student’s t test. A p-value of <0.05 was considered significant.

**RESULTS**

Initially, the ECV 304 cells were exposed to 20 ng/mL VEGF₁₆₅ to determine the effect of VGEF on cell growth. The VEGF₁₆₅ protein was found to significantly increase the number of cells by almost 2.2 times after 24 hr, and by 2.5 times after 48 hr (Fig. 1A).

To investigate the effect of VEGF₁₆₅ on eNOS activity, after treating 20 ng/mL VEGF₁₆₅ in an arginine substrate for 24 hr, the concentration of citrulline produced by the NOS enzyme was measured. The results showed that NOS enzyme activation was increased by two-fold in the cells treated with the VEGF₁₆₅ protein, compared with the control group that was not treated with the VEGF₁₆₅ protein (Fig. 1B).

To determine whether the increase in NOS activity observed in the ECV 304 group was the result of eNOS protein expression, the expression of the eNOS and inducible NOS (iNOS) protein was measured after exposing the ECV 304 cells to VEGF₁₆₅ concentrations ranging from 5 ng/mL to 20 ng/mL for 24 hr. In the cells treated with the VEGF₁₆₅ protein, eNOS protein expression (about 130 kDa) was increased in a dose-dependent manner, and eNOS protein expression in the endothelial cells exposed to 20 ng/mL VEGF₁₆₅ for 24 hr increased by approximately two-fold compared with the control cells (Fig. 2). However, iNOS expression was not
detected.

To examine whether the increased eNOS protein and the enzyme activation was due to the increase in the mRNA, the amount of mRNA was determined by RT-PCR. After separating the total RNA from the cells harvested after VEGF165 protein treatment (0-20 ng/mL) for about 6 hr, RT-PCR was conducted using VEGF-specific primers. The result showed that the amount of β-actin expression used as an internal control was constant, while 296 bp bands that were thought to be the product of eNOS PCR increased by 1.1, 1.8, and 2.2 times when exposed to VEGF concentrations of 5, 10, and 20 ng/mL, respectively (Fig. 3).

To examine the involvement of PI-3K in eNOS expression by VEGF, the endothelial cells were exposed to VEGF165 after 1 hr pretreatment with LY294002 or wortmannin, which are well known as PI-3K inhibitors. In the cells pretreated with 10 μM or 20 μM of LY294002, the eNOS expression induced by VEGF165 was suppressed depending on the concentration of the inhibitor (Fig. 4A). In the group not pretreated with LY294002, eNOS mRNA expression increased by 1.7 times, whereas in the group pretreated with 20 μM of LY294002, it decreased to the same level as of the control group (Fig. 4B). This shows that PI-3K inhibitor inhibits eNOS mRNA expression by VEGF165. Furthermore, eNOS protein expression by VEGF165 increased by 2.2 times, compared with 1.6 times when it was exposed to VEGF165 after pretreatment with wortmannin, the other PI-3K inhibitor (Fig. 5).

Because there are some reports showing that the eNOS activation in endothelial cells by VEGF165 is controlled by ERK1/2, which is a downstream molecule and a type of MAPK, the effect of kinase phosphorylation on eNOS expression was examined. eNOS protein expression by VEGF165 was measured after pretreatment with PD98059, which is a known ERK1/2 cascade inhibitor. As shown in Fig. 6, PD98059 pretreatment suppressed the VEGF-mediated eNOS expression (Fig. 6).

To examine whether or not eNOS expression by PD98059 correlates with ERK phosphorylation, immunoblotting was carried out using antibodies for phospho-ERK, an activated form of ERK. As a result, ERK phosphorylation was increased by the VEGF165. However, there was no significant change in p38 MAPK phosphorylation (Fig. 7). Furthermore, LY 294002 or PD98059 attenuated the ERK phosphorylation...
DISCUSSION

Recent studies have shown that VEGF increases NO production in rabbit or human endothelial cells, and NO is thought to be an important mediator in VEGF-induced endothelial cell proliferation (16, 18). For the basic mechanism of the induction of NO by VEGF, some reports have shown the inhibition of VEGF-induced endothelial cell proliferation by the NOS inhibitor, the inhibition of reticular formation of endothelial cells in three-dimensional collagen gel (12, 19), and that NO produced by substance P or VEGF stimulates bovine endothelial cell proliferation (12, 20). Using ECV 304 endothelial cells, we observed the proliferation of endothelial cells induced by VEGF and an increase in NO activity. This suggests that NO is an important mediator in VEGF-induced endothelial proliferation.

The fact that the increase of NO through a brief exposure to VEGF is reduced by the tyrosine kinase inhibitor, calcium-chelating compounds, and PI-3K suggests that the NO increase is associated with an activation of tyrosine kinase and PI-3K and an increase in the cellular calcium concentration.
Thus, the exposure of human umbilical vein endothelial cells to VEGF results in an increase in the cellular calcium concentration, while treatment with calcium-chelating compounds or calmidazolium results in a decrease of VEGF-induced NO production (9, 19). On the other hand, the chief mechanism of NO production through 24 hr or more of continuous VEGF stimulation is thought to be due to an increase in NOS protein synthesis (7, 19, 21). It was thought that eNOS (type III NOS) is always activated in endothelial cells and its enzymatic activation is partially regulated by intercellular Ca\(^{2+}\), while iNOS (type II NOS) is regulated at the transcription level. However, recent studies have suggested that eNOS protein expression can also be regulated by physical stress or hormone. The increase in eNOS expression by such stimuli as the transforming factor β (22), a basic fibroblast growth factor (23, 24), fluid shear stress (25), and hypoxia (26) has been reported. Moreover, continuous physical exercise on dogs has been shown to increase eNOS expression and the consequent benefits of exercise on the vascular system has been reported (27). This study confirms that the increase of eNOS protein by VEGF at the mRNA level. The results also show that the increase in NO synthesis is through to be not only due to a simple increase in NOS activity, but also due to an increase in the NOS protein at the transcriptional level. iNOS expression was not increased by VEGF in contrast to Papapetropoulos et al. (19).

Tyrosine kinase is known to participate in the signal transduction and expression of eNOS induced by VEGF. In human endothelial cells, tyrosine kinase inhibitors such as genistein and geldanamycin inhibit NO synthesis through VEGF. At least two receptors, Flt-1 and Flk-1/KDR, are involved in the mechanism of action of VEGF and the cells expressing Flk-1/KDR show more cell structural changes and cell proliferation than those with Flt-1 (5). However, Flk-1/KDR receptor activation through VEGF shows increases in eNOS and iNOS protein expression, but Flt-1 receptor stimulation does not increase NOS protein expression (21). Each one of these receptors has endogenous tyrosine kinase activity. In addition to these receptors, at least 11 proteins, such as phospholipase C-γ, PI-3K, Ras GTPase activating protein (GAP), and Nck (oncogenic adaptor protein), are activated through tyrosine phosphorylation (28). Among the tyrosine phosphorylated proteins, there is also ERK1/2, a number of the MAPK family. In human umbilical vein endothelial cells, VEGF increases tyrosine phosphorylation of the Flk-1/KDR receptors and both receptors phosphorylate and activate the p85, a regulating unit of PI-3K. It then activates MAPK (29). ERK1/2 plays a central role in the growth and proliferation of various cells, in the increase of eNOS expression through VEGF treatment, and consequently in the neovascular formation by VEGF. Studies have shown that the pretreatment with PI-3K inhibitors in human umbilical vein endothelial cells inhibits NO formation through VEGF (19). However, the actual mechanism of PI-3K-associated NO synthesis is still unknown. It is also unclear whether this is due to a simple increase in NO activity or due to changes in NOS protein synthesis. The present study revealed that the pre-treatment with PI-3K inhibitor, LY294002 or wortmannin, attenuated the eNOS expression in response to VEGF. LY294002 showed a higher degree of inhibition than wortmannin. Furthermore, the pre-treatment with the ERK1/2 inhibitor, PD98059, decreased eNOS expression by VEGF and phosphorylated ERK1/2. Both PI-3K inhibitors, LY 294002 and wortmannin, inhibited ERK1/2 phosphorylation by VEGF. These results suggest that both PI-3K and ERK1/2 pathways play a major role in NOS protein synthesis by VEGF.

In conclusion, NOS protein synthesis is one of the key mechanisms responsible for the increase in NOS activity induced by VEGF and PI-3K and ERK1/2 are deeply involved in VEGF-induced eNOS expression in ECV 304 cells.

ACKNOWLEDGMENT

This study was supported by a research grant (1999) from the Institute of Basic Medicine and Research Institute of Clinical Medicine, Yeungnam University.

REFERENCES

1. Shweiki D, Ilut A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.  
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.  
3. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.  
4. Terman BI, Dougher-Vernazen M, Carrion ME, Dimitrov D, Armelino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-86.  
5. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.  
6. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-6.  
7. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-95.  
8. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of recep-
tor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271: 5638-46.
9. Brock TA, Dvorak HF, Senger DR. Tumor-secreted vascular permeability factor increases cytosolic Ca\(^{2+}\) and von Willebrand factor release in human endothelial cells. Am J Pathol 1991; 138: 213-21.
10. Wu HM, Huang Q, Yuan Y, Granger HJ. VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol 1996; 271: 2735-9.
11. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265: 586-92.
12. Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996; 270: 411-5.
13. Ziche M, Morbidelli L, Choudhari R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-34.
14. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995; 91: 2793-801.
15. Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Passeri J, Symes JF, Isner JM. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF\(_{165}\) gene transfer. Am J Physiol 1994; 267: 1381-8.
16. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998; 73: 4220-6.
17. Yu Y, Sato Y. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999; 178: 235-46.
18. Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41: 773-80.
19. Papapetroupolos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cell. J Clin Invest 1997; 100: 3131-9.
20. van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekatat C, Isner JM. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95: 1030-7.
21. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998; 27: 743-6.
22. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vase Biol 1995; 15: 1255-61.
23. Kostyk SK, Kurembanen S, Wheeler EL, Medeiros D, McQuillan LP, D’Amore PA, Braunhut SJ. Basic fibroblast growth factor increases nitric oxide synthase production in bovine endothelial cells. Am J Physiol 1995; 269: 1583-9.
24. Arnal JF, Yamin J, Dockery S, Harrison DG. Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. Am J Physiol 1994; 267: 1381-8.
25. Namao M, Ohara Y, Navas JP, Nishida K, Murphy TJ, Alexander RW, Nerem RM. Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. Am J Physiol 1995; 269: 1571-8.
26. Xu XP, Pollock JS, Tanner MA, Myers PR. Hypoxia activates nitric oxide synthase and stimulates nitric oxide production in porcine coronary resistance arteriolar endothelial cells. Cardiovasc Res 1995; 30: 841-7.
27. Sessa WC, Prichard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994; 74: 349-53.
28. Gao D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995; 270: 6729-33.
29. Thakker GD, Hajjar DP, Muller WA, Rosengart TK. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999; 274: 10002-7.